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Abstract
Background: Several diseases, many of which nowadays pandemic, consist of multifactorial
pathologies. Paradigmatic examples come from the immune response to pathogens, in which cases
the effects of different infections combine together, yielding complex mutual feedback, often a
positive one that boosts infection progression in a scenario that can easily become lethal. HIV is
one such infection, which weakens the immune system favouring the insurgence of opportunistic
infections, amongst which Tuberculosis (TB). The treatment with antiretroviral therapies has
shown effective in reducing mortality.
An in-depth understanding of complex systems, like the one consisting of HIV, TB and related
therapies, is an open great challenge, on the boundaries of bioinformatics, computational and
systems biology.
Results: We present a simplified formalisation of the highly dynamic system consisting of HIV, TB
and related therapies, at the cellular level. The progression of the disease (AIDS) depends hence on
interactions between viruses, cells, chemokines, the high mutation rate of viruses, the immune
response of individuals and the interaction between drugs and infection dynamics.
We first discuss a deterministic model of dual infection (HIV and TB) which is able to capture the
long-term dynamics of CD4 T cells, viruses and Tumour Necrosis Factor (TNF). We contrast this
model with a stochastic approach which captures intrinsic fluctuations of the biological processes.
Furthermore, we also integrate automated reasoning techniques, i.e. probabilistic model checking,
in our formal analysis. Beyond numerical simulations, model checking allows general properties
(effectiveness of anti-HIV therapies) to be verified against the models by means of an automated
procedure. Our work stresses the growing importance and flexibility of model checking techniques
in bioinformatics.
In this paper we i) describe HIV as a complex case of infectious diseases; ii) provide a number of
different formal descriptions that suitably account for aspects of interests; iii) suggest that the
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Open Accessintegration of different models together with automated reasoning techniques can improve the
understanding of infections and therapies through formal analysis methodologies.
Conclusion: We argue that the described methodology suitably supports the study of viral
infections in a formal, automated and expressive manner. We envisage a long-term contribution of
this kind of approaches to clinical Bioinformatics and Translational Medicine.
Background
Human diseases result from abnormalities in an
extremely complex system of molecular processes that
are often caused by viral or bacterial infections. In these
pathological processes, virtually no molecular entity acts
in isolation and complexity is caused by the vast amount
of dependencies between molecular and phenotype
features. The key player of the human survival is the
immune system which is a complex system that can be
described as a large network of dynamical agents (cells
and signalling molecules). A great challenge for con-
temporary molecular medicine is the modelling, descrip-
tion and ultimately the comprehension of the multistep
and multiscale nature of the immune response to
pathogens. An even greater challenge is when viral and
bacterial infections occur together in the same patient.
TB, which is caused by Mycobacterium tuberculosis, is
the most frequent co-infection in patients infected by the
human immunodeficiency virus type 1 (HIV-1). TB
makes more complicated the development of effective
therapies.
Efforts for gaining further insights into the pathological
mechanisms and novel therapeutic targets benefit from
the integration of genomic, proteomic, metabolomic and
environmental information. In this work we follow an
integrated approach that relies on several sources, such
as phylogeny information, traditionally explored within
Bioinformatics, differential equations and stochastic
modelling, both largely used in Systems Biology, and a
formal reasoning technique, viz. Model Checking,
developed in Theoretical Computer Science to assess
properties of complex computational systems. Further-
more, the Bioinformatics approach in the study of viral
dynamics has also focused on identifying variable
regions in genomes and pathogenic islands in bacteria
[1]. These integrated frameworks appear to be effective
for the research in the biomedical problems.
Mathematical and computer science approaches have
shown to be more effective in dissecting the network
connectivity of cellular circuits and the corresponding
dynamical characteristics. The mathematical description
of the variation of biomolecular concentrations as a set
of ODEs offers quantitative basis for predicting the
behaviour and evolution of the system and for testing
non-linearities. An alternative approach is to use
stochastic simulation via the Gillespie algorithm which
provides an exact algorithmic solution of a set of
reactions and a meaningful way to consider the noise
[2]. The use of mathematical models in immunology has
been very successful and has represented an insightful
and essential complement to in vivo and in vitro
experimental design and interpretation. Kinetic Model
suggests that HIV-1 in vivo is continuous and highly
productive and that leads CD4 T cells count low [3].
Nowak and May has proposed a simple model on HIV
dynamics by considering population of non-infected T
cells, infected T cells and viral population [4]. Perelson
has proposed mathematical models on interaction of
HIV virus and T cells dynamic by considering one more
variable (un-infectious viruses) [5]. The HIV quasi-
species models have been inspired from the molecular
quasi-species model in chemistry [6,7]. Indeed mathe-
matical models of HIV dynamics have proven valuable
in understanding the mechanisms of many of the
observed features of the progression of the HIV infection,
see for example [3,6-13]. In this paper we model
c o i n f e c t i o no fH I Va n dT Ba n dt h ee f f e c to fH A A R T
therapy on the model dynamics.
Recently, the observation that biological systems often
exhibit interactive and concurrent behavior, similarly to
computational concurrent systems, has led to the
adoption of formal methods originally developed for
the description and analysis of complex software systems
in computer science. This abstraction “cell as computa-
tion”, similar to the “DNA as string” and “protein as
labeled graph” abstractions which have originated
bioinformatics, has inspired the adoption of model
checking methodologies to validate biological complex
systems [14]. The growing success of model checking
(see for instance [15-18]) relies in the specification of a
biological property of interest which is expressed in a
formal language, typically a formula of a suitable logic,
and its verification is carried out by a fully automated
procedure that returns either a positive response or a
counter example [19].
The aim of this paper is to pipeline bioinformatics and
quantitative models of infectious processes and anti-HIV
therapies, and then show how model checking
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silico results obtained from quantitative models of
infectious diseases dynamics. Given that viral infections
and the functioning of therapies often present stochastic
aspects, we introduce a succinct but descriptive stochastic
model of HIV infection associated with TB opportunistic
infection. Then we extend it by modelling (the effects of)
HAART anti-HIV therapy. These models have then been
implemented in PRISM, a state of the art probabilistic
model checker supporting a logical language [20]. We
illustrate, by means of two simple properties, the flavour
of the verification made possible by these techniques
and how this can contribute to a precise assessment of
the information conveyed by the mathematical models.
The complexity of HIV infection and anti-HIV therapies
Human immunodeficiency virus type 1 (HIV-1) infec-
tion is characterised by the progressive loss of CD4 T
cells. Anti-HIV therapies act to eradicate or lower the
concentration of the virus from the body and replenish
the CD4 T cells reservoir. Infection by most strains of
HIV requires interaction with CD4 T cells and a
chemokine receptor, either CXCR4 or CCR5. Viral strains
often use CCR5 during early stages of HIV-1 and then
switches to CXCR4 to enter into the cells. This switch
emerges in more than 50% of patients [21,22] and it has
been linked with progression to AIDS because of an
increased virulence through the formation of cell
syncytia and the stimulation of the cellular factor called
Tumour Necrosis Factor (TNF) which inhibits the
replication of R5 HIV strains while has no effect on X4
HIV [23,24].
It takes on an average 10 years to get infected by AIDS
after having HIV infection. Some patients died within 2
years after getting infected by HIV, while others
remained free of AIDS for more than 15 years. The
within-patient evolutionary process of viral sequence
mutations during HIV infection has suggested improve-
ments in anti-HIV therapies. Anti-HIV drugs are most
effective when taken in a combination of three or more
at the same time. This is called combination therapy or
HAART (Highly Active Antiretroviral Therapy). Physi-
cians recommend starting the therapies if you are ill
b e c a u s eo fH I V ,o ri fy o u rC D 4Tc e l l sc o u n ti fl o w
(below 200 cells per microL). HAART combinations
usually include two drugs that are nucleoside analogues,
and one protease inhibitor. The nucleoside analogues
drugs result in targeting the viral reverse transcriptase
which codes the viral RNA into the DNA that can be
integrated into human cells, so transforming the cell into
a factory for building blocks of the virus. The protease
inhibitor acts as preventing an infected cell from
producing new infectious virus particles.
Bioinformatic links between HIV and TB
Chemokines provide the key link between HIV and TB
infection. Resistance to HIV infection has been found to
be related to the following mutations. Delta32 CCR5,
190G CCR2 and 744A CX3CR1 and CCL3L1 [25]. The
chemokine receptor CXCR3 can exhibit weak coreceptor
function for several human immunodeficiency virus,
both HIV-1 and HIV-2 strains and clinical isolates [26].
Gene expression data analysis of HIV infected macro-
phages showed large changes in beta-chemokines and
RANTES (CCL5) [27]. The TB infection is known to
produce larger effects than HIV infection on the
chemokine networks. TB is associated with excess
monocyte chemoattractant protein (MCP)-1 and Tumour
Necrosis Factor (TNF)-alpha activity in situ, both are
implicatedintranscriptionalactivationofHIV-1[28].Itis
also important to mention significant elevation of the
chemokinesCCL3,CCL4andCCL8[29].Geneexpression
data analysis of TB infected macrophages versus unin-
fected, showed upregulation of the following genes.
interleukin-1 beta and interleukin-8, macrophage inflam-
matory protein-1 alpha, growth-related oncogene-beta,
epithelial cell-derived neutrophil-activating peptide-78,
macrophage-derived chemokine [30]. The most impor-
tant mechanism through which TB enhances HIV-1
replication and the progression to AIDS in dually infected
patients is the augmentation in expression of TNF-alpha
and the HIV-1 noninhibitory beta-chemokine (MCP-1),
low presence of HIV-1 inhibitory beta-chemokines (MIP-
1 alpha, MIP-1 beta, and RANTES). We have collected a
set of human aminoacid sequences of all the chemokine
receptors known to chemokines involved in HIV and
tuberculosis and a set of control chemokine receptors. We
have built a phylogenetic tree that describes the statistical
relationship between those chemokine receptors (see
Figure 1). The tree was generated using maximum
likelihood on an alignment of the sequences of the
external regions of the protein loops. In violet the
chemokines receptors disrupted by both TB and HIV; in
red those disrupted by HIV. Note that the switch between
CCR5 and CXCR4 may involve other chemokine recep-
tors. This may suggest to concentrate some efforts on
therapies by intervening by blocking other chemokine
receptors disfunction.
The disruption caused by the dual infection (HIV and
TB) focuses on RANTES which blocks CCR5 and whose
expression is upregulated by TNF. Therefore we incorpo-
rated TNF in our deterministic model to predict the
potential effect of HAART on coinfection of HIV and TB.
That evidence would explain the increase in CXCR4
usage with the increase of TNF concentration [31]. The
relationship between HIV and TB seems to be very
profound since quasispecies of both HIV and TB
influence each other differently [32,33]. Our
BMC Bioinformatics 2010, 11(Suppl 1):S67 http://www.biomedcentral.com/1471-2105/11/S1/S67
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synergically and not simply additively to alter the
chemokine network.
Results and Discussion
Although differential equation models have long been
used for the immune system and viral infection
modelling, they focus on the average behavior of large
populations of perfectly mixed, identical individuals. An
improved realism is perhaps provided by stochastic
simulations, which however are computationally inten-
sive. Given that differential equations and stochastic
descriptions have important pros and cons and a good
degree of complementarity, a framework based on the
implementation of both approaches, although time and
resources expensive, appears advisable. Stochastic mod-
els, then, support the well developed probabilistic model
checking analysis. We have extended a model firstly
presented in [7]. We have incorporated the Cytotoxic T
Lymphocytes (CTLs) response and the dynamics of TB
opportunistic infection so as to analyse the co-infection
of HIV strains and another disease associated with it.
Furthermore, we have introduced an abstract representa-
tion of the HAART therapy treatment by altering the
model’s parameters that rule the dynamics of our model
according to the known effects of the treatment. We are
presenting results of the analysis of the HIV and the
opportunistic TB infection dynamics and an associated
therapy through differential equations, stochastic mod-
elling and formal reasoning techniques.
HIV and the opportunistic TB infection
Experiments carried out by means the deterministic model
are reported in Figure 2. Details about the construction of
the model are reported in the Methods section. For the
sake of space we do not show the sensitivity analysis of
the deterministic model. Experiments with the model are
able to faithfully reproduce well known curves of the virus
and CD4 T cells dynamics in absence of TB. The
introduction of TB provides a novel description of the
dynamics occurring with this infection where viral load
increases suddenly in the last stage of HIV-1 (AIDS)
because of opportunistic diseases (TB) (see [33]). In
particular, Figure 2(a) shows the behaviour of CD4 T cells
during the switch between R5 and X4 strains. The general
dynamics of CD4 T cells and viral load can be observed. In
the latest stage of HIV-1 infection (opportunistic diseases
stage) a sudden increase of the viral load can be observed,
which lead to AIDS. The increase of TNF against the viral
load time course is reported in Figure 2(b). This TNF
dynamics provide a clear explanation of the quick growth
of viruses when TB infection occurs. TB and X4 strain of
HIV stimulate TNF production which, in turn, help them
to progress at faster rate.
Modelling HAART therapy against HIV and TB
The model of HIV and TB co-infection can easily be
extended to embrace the effect of a common anti-HIV
treatment such as the HAART. Drug therapies such as
HAART and Maraviroc, althoughw i t hd i f f e r e n tm e c h a n -
isms, result in decreasing the number of viruses and the
death of infected cells. Exploiting the expressivity of the
treatment, we model HAART in terms of its effects. For
the sake of simplicity this can be done by changing the
virus replication rate (π, see Methods), reflecting a
decreased replication rate and budding from the infected
cell. Simulation results are reported in Figure 3. Plots (a)
and (b) show the effect of the HAART therapy delivered
before and after the appearance of the X4 strain,
respectively and before (c) and after (d) the TB infection,
respectively. Clearly, both the appearance of X4 and the
Figure 1
The maximum likelihood phylogeny under the JTT
model of evolution for a set of chemokine receptors
amino acid sequences.
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Viral load, CD4 T and TNF over the course of time. (a) Time evolution of viral load and CD4 where mutation of V5
leads to V4 at around day t = 900 and opportunistic diseases (TB) appears at around day t = 2900 (b) dynamics of viral load and
TNF over time.
Figure 3
Experiments with HAART therapy. Therapy start from (a) day t = 250 to day t = 350 (b) day t = 950 to day t = 1050 (c)
day t = 2250 to day t = 2350 and (d) day t = 3150 to day t = 3250.
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Tc e l l sw h i c ht h eH A A R Ti sa b l et os t o pb u tn o tt o
completely reverse. An early start promulgated HAART
treatment will change the probability of arising of X4
(this results was obtained by Sguanci et al). Here we
show that short HAART treatments have small effect if
administrated when CD4 T cells count is above 200 and
they have even smaller effect when CD4 T cells counts
are below 200.
A stochastic description of HAART, HIV and TB dynamics
Many natural and biological phenomena are intrinsically
stochastic and discrete, and they can not always be
properly described by means of a deterministic and
continuous description. For instance, systemic emergent
properties can be sensitive to the local presence of
minimal (integer) quantities of molecules [34]. Roughly
speaking, a stochastic model associates a probability to
each state transition of the modelled system, expressed as
a rate associated to the transition. Associated probability
distributions are typically memoryless, and hence the
overall system behaviour can be interpreted as a Markov
Chain. Often, models are used to simulate possible
evolutions of the system from initial conditions, [35].
Starting from the deterministic model of HIV, TB and
HAART, we have determined a corresponding stochastic
model. This has been done via standard transformation
from deterministic rates into stochastic ones, according
to a fixed reference volume of the model (see, e.g., [36]).
Simulation results are reported in Figure 4 about the
dynamics observed for a specific possible evolution of
the system (chosen according to the probability dis-
tribution determined by the model). From Figure 4 (left)
it emerges that CD4 T cells, representative of the immune
system health, go quickly down in the massive presence
of the X4 viral strain. As soon as CD4 T is below a
threshold limit, 20 units on the scale of this model, TB
develops and the viral load saturates. This reproduces, on
a small scale, the general time course at individual level,
like the one reported in Figure 2. In Figure 4 (right) a
simulation under the same initial conditions is shown.
In this case, the HAART treatment has been administered
starting at a quite early time point (after few tenth of the
initial second) and then stopped (at about 2.5 seconds).
It can be observed that, even if HIV progression weakens
the immune system, it never goes below the threshold,
but rather the viral load seems quite well controlled. In
the short interval, HAART prevented the development of
TB once started before its insurgence. However the viral
load upraises after the interruption of the therapy. The
stochastic modeling approach shows important advan-
tages, such as the possibility of pipelining with the
probabilistic model checking and some limits in the
computational intensive requirement. Work in progress
will make use of grid computing facilities (EGEE and
Cambridge) and cloud facilities.
Assessing HAART therapy against HIV and TB infection
Observing the quantitative results of the stochastic
simulations in Figure 4, one can have an idea about
the fact that the HAART therapy is somehow effective.
However, we discuss now an example on how it is
possible to move from a correct and informative, but
somehow empirical, interpretation of data, as the idea
Figure 4
A limited fragment of the time course of Viruses, CD4 T cells and TB bacteria in the case of (a) no treatment
and (b) treatment with HAART.
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specifying properties of interest as logical formulae. This
has the advantage of requiring a definition of all the
aspects of interest, of referring to a formal and unambig-
uous semantics, and of having an automated procedure for
verifying formulae (as the one we adopted [20]).
Differently, observations rely on the capability of properly
interpreting the graphs, which sometimes may appear
obscure and difficult to interpret. More details about the
methodology can be found in the Methods section.
Therapy effects
We focus on two properties that can give a measure of
the infection progression.
i) we consider the number of infected cells leading to
virus replication as a measure of the spread of infection.
We are interested in measuring how often this can occur.
This can be expressed by a formula like
Ri t o v C {" "} ? [ . ] __ =< = 50
where R{"i_to_v"} represents the number of occurrences
of an event labelled with i_to_v,i . e .t h et r a n s i t i o nf r o m
an infected CD4 T cell to virus replication. The question
mark says we are interested in determining the number
of such possible occurrences in the model dynamics. C <
5.0 stands for the time interval;
ii) we consider the amount of healthy CD4 T cells,
represented by variable tc,a sam e a s u r eo fr e s i s t a n c et o
the virus attack. We are interested in the probability that
tc is less than the threshold 20. Here ? requires the
computation of a probability and F [...] tc <= 20 is a logic
term expressing that the event tc <= 20 occurs within the
interval [...]:
PF t c =< = ?[ [ . ,. ] ] 0050 2 0
Experimental results
The analysis has been performed using the PRISM model
checker (see Methods section). Properties can be vali-
dated either by constructing the complete Continuous-
time Markov Chain relative to the given model model or
by approximating verification through sampling a certain
number of possible evolutions. The former can result
costly or unfeasible for large models. Adopting the latter
we obtained the results reported in Table 1.
Automated verification yields quantitative measures of
the investigated properties. While the number of viral
replications due to CD4 T cell infection is comparable
(but without HAART many other infected cells con-
tribute to virus replication), the probability of a failure
of the immune system is much stronger without HAART
treatment, closely to twice as much as.
Conclusion
We have illustrated the potential benefits of formal
methods and quantitative models when applied to the
study of viral infections and therapy assessment within a
computational bioinformatics approach. We have done
this by presenting experiments on a proof-of-concept
scenario regarding HIV infection and the relative TB
opportunistic infection. We have adopted an integrated
approach, combining deterministic and stochastic tech-
niques and illustrating how properties of interests for the
study of viral infections can be formalised in a general
purpose logic, as the one supported by PRISM. Our work
stresses the growing importance and flexibility of model
checking techniques in bioinformatics. Noteworthily, the
verification of these properties can precisely characterise
the numerical results of simulations, and this can be
helpful in comparing and assessing different antiviral
therapies. In conclusion, the modelling of HIV infection
has two important linked benefits. i) it has matured to
the stage of allowing us to combine bioinformatics,
computational modelling and formal reasoning techni-
ques, as model checking, i.e. it provides a solid bridge
between biological systems and the computational
objects used to describe them; ii) these approaches
together capture information that can be valuable in
therapy validation suggesting the possibility of moving
in the future to realistic cases, i.e. translational medicine
and clinical bioinformatics.
Methods
In this section we provide further details about the con-
struction of the used models and analysis methodologies.
A deterministic model of HIV strains
and TB time evolution
Our work is based on a deterministic model of HIV-1
dynamics, firstly appeared in [7], which takes into
account the models developed by Perelson and his
followers [3,10,13,37]. These models are well presented
Table 1: Quantitative results from the automated verification of
the effects of HAART therapy. While the number of viral
replications due to CD4 T cell infection is comparable with and
without HAART treatment for the time interval considered, a
much stronger probability of a failure of the immune system,
close to twice as much as, is observed without the HAART
treatment
HIV+TB HIV+TB+HAART
R{"i_to_v"} = ? [C < = 9.0] 250 269
P =?[ F[5.0, 8.0]tc < = 20] 0.885 0.429
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initial model has been extended here by adding two more
variables, Cytotoxic T Lymphocytes (CTLs) cells and TB,
to capture dynamics of co-infection of HIV and TB.
Asstandard,wedescribethevariationsofthequantitiesof
the modelled entities as aset of differential equations. We
start considering a pool of immature CD4 T cells,
represented by the variable U, see equation (1). These
cells are continuously produced by the thymus at a rate
NU, and evolve into differentiated, uninfected T-cells, T at
a rate δ
U. Also, the TNF (F) contributes to the clearance of
naive T-cells, via δ F
U , and naive T cells are produced at fix
rate kZ due to CTLs (Z) response. T cells (T) are described
byconsideringtheirdifferentstrains(Ti),whichwedonot
detail here (see [7]). Beyond being produced, they can
become infected (Ik) by interacting with the virus strains
Vk at rate bk,ordi ea tr at eδ
T, (equation (5)). Note that the
infection parameter b is not constant over time, but
depends on the distribution of the viral strains R5 and X4
[9]. Infected T cells are cleared out at a fixed rate, δ
I,a n d
a l s od u et ot h ea c t i o no fC T L sw i t hr a t eδI
Z , (equation
(2)). Equation (6) describes the budding of viruses, i.e.
infected cells produce new viruses at rate π, and the fact
that virus particles may be nonviable or being cleared out
at rate c by immunoglobulin binding and subsequent
engulfments by the macrophages. Next equation (3)
describes latent TB (B) in the blood which propagates
with the rate a when T cells goes below a given threshold
representing the efficacy of the immune system. The
equation (7) describes the TNF (F) dependence on X4
strainsand onthe presence of TB in the blood and the fact
that the efficacy of such a factor naturally decay in time.
Finally, the response of Cytotoxic T Lymphocyte cells Z is
as in equation (4): CTLs response depends on number of
infected cells (I) and is cleared out at fixed rate b.T h i s
model is general enough to be used as a framework for
fitting real data and simulating superinfection and co-
infection patterns.
dU
dt
NU U F k I Z U
U
F
U
Z =− − + δδ (1)
dIk
dt
VT I I Z kk k k
k
i
i
I
I
Z =
⎛
⎝
⎜
⎜
⎞
⎠
⎟
⎟
⎛
⎝
⎜
⎜
⎞
⎠
⎟
⎟
−− ′′′
′ ∑∑ μβ δ δ (2)
dB
dt
BB Z Z
B =− αδ (3)
dZ
dt
IZ bZ I
Z =− δ (4)
dTi
dt
UV T T
U
kk i
T
i
k
=− − ∑ δβ δ () (5)
dVk
dt
Ic V kk =− π (6)
dF
dt
KV K B F Fk B
F
kX
=+ −
∈ ∑ δ
4
(7)
The stochastic model
The stochastic model has been derived from the
deterministic one. As a simplification we consider only
two viral strains: R5 viral strain (V5) and X4 viral strain
(V4), and correspondingly only two kinds of infected
cells (I4, I5 and I* for the union of the two).
Analogously, quasispecies dynamics revert to V5s t r a i n s
that transform into V4 strains (at rate bk54). These two
strains are the ones we focus on when observing the time
course of infections. As for the deterministic model, we
have included sufficient details of interaction among the
species to express the properties of interest.
As mentioned, we needed to translate some parameters
from deterministic to stochastic ones, accordingly to the
reference volume of interest. Other parameters, particu-
larly due to lack of existing data in literature, have been
approximated by tuning the model on known macro-
scopic behaviour. We considered a volume of reaction
large enough to contain a statistical reliable number of
agents (viruses and cells) and values of extensive
quantities are scaled according with the reaction volume
considered.
We employ a population-based approach where the
number of each type of species or cells are modelled,
rather than the state of each individual component.
Furthermore, also according to the PRISM modeling
language we used, we rewrote the equations of the
deterministic model in terms of a “reaction-centric”
description. dynamics is represented by a set of reaction
rules stating the involved entities and the results of
interaction. These are reported in Table 2. Reaction
(02) stands for the production of T cells from naive T
cells, while (04) and (05) represent viral infection.
Stochastic parameters are on the right part of the Table.
Interestingly, parameters a and δ Z
B vary to reflect the
emergent behaviour of TB infection against the effi-
ciency of the immune system. when below to a given
threshold, the exponential growth of the HIV virus load
appears, caused by the spreading of the infection to
other cells and abstractly modelled here by such a set of
ad-hoc rules. Initial population of cells in the model is:
U = 30, T = 50, I =3 0 ,Z = 30, F =0 ,V4 =5 0- V5, V5 =
50, B = 10, and the immune deficiency threshold is set
to 20.
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has been modelled by means of a stochastic triggering
event that activates and deactivates the treatment.
Activation consists in the modification of interactions
(12) and (13), whose rate is downgraded to 1,
representing reduced morbidity of the virus, which is
o n eo ft h em a i ne f f e c t so fH A A R T .
Probabilistic Model Checking
Being an introduction to probabilistic model checking
beyond the scope of this paper, we refer the interested
reader to the cited literature and references therein.
Other recent works are [15,16,38]. We introduce
informally the main concepts by examples.
The information encoded in a stochastic model
describes, roughly speaking, the states in which the
modelled system can find itself and the associated
probability of being in a state at a certain time. For
many natural phenomena that follow a memory-less
probability distribution this amounts to a (Continuous
T i m e )M a r k o vC h a i n( C T M C ) .F u r t h e r m o r e ,g i v e na
stochastic model, several algorithms to simulate the
possible quantitative evolutions of the system have been
defined, noticeably the Gillespie’s algorithm [2]. State
semantics, such as Transition Systems, have been
extensively studied and used to precisely describe the
behaviour of dynamical systems, like distributed and
concurrent computational systems. State semantics may
often become hardly manageable due to the exponential
explosion of the number of states. However, several
efficient and automated analysis techniques have been
defined. Logical formulas can represent “homogeneous”
sets of states. A formula like
◊a.φ
can be used to represent the set of states in which an
“a-kind-of” transition can occur and the system evolves
into a state fulfilling, in turn, the formula j.I nas e n s e ,
the states of the semantics become the model of the
formula of interest. The problem of the verification of a
formula against a state semantics is known as Model
Checking [ 1 9 ]a n dy i e l d se i t h e ra na f f i r m a t i v ea n s w e ro ra
counter example, e.g. a set of states not fulfilling the
formula. Most of the times, the model checking
procedure is fully automated. Logics [39] and model
checking procedures [40] have been defined for prob-
abilistic state semantics, that is Probabilistic Model
Checking. A typical logic may express formulas like
Pp >  [] φ
which, informally speaking, represents all the traces for
which j holds with probability bigger than p.O t h e r
examples are F >= tx> 2, the traces in which eventually x
>2a f t e rt time units, and Gx<1 0 ,globally,f o ra l lt h e
traces, the value of x is less than 10.
PRISM
The PRISM probabilistic model checker [20] is a tool for
formal modelling and analysis of systems that exhibit
random or probabilistic behaviour. Beyond CTMC,
PRISM also supports DTCM and Markov decision
processes [41]. PRISM has been chosen as it is one of
the reference existing model checker, free and open
source. However, its features are not determinant here,
and other similar platforms could have been chosen.
PRISM models are specified in a formal language that
describes the entities present in the model, their
Table 2: Interactions in the stochastic model. The values of the
parameters are from literature referred (for sake of clarity we
skip the dimensionality which is the standard reported in
literature), see also [42-44], or obtained by tuning of the model
(01) DU dU U
NU
→+ NU = 100
(02) UT
U
→
δ
δ
U=0 . 1
(03) UF F
F
U
+→
δ
δ F
U = 0.00001
(04) TV I
k
+→ 55
5 β
bk5 = 0.0025
(05) TV I
k
+→ 44
4 β
bk4 = 0.0025
(06) VV
k
54
54
→
β
bk54 = 0.025
(07) T
T
→
δ
0 δT =0 . 1
(08) I
I
40 →
δ
δI =0 . 8
(09) I
I
50 →
δ
δI =0 . 8
(10) IZ U IZ
kZ * +→+ +
∗ kZ =0 . 0 1
(11) IZ Z
I
Z
* +→
δ
δI
Z = 0.004
(12) IV 5 100 5 +→ ×
π
π =2 . 5
(13) IV 4 200 4 +→ ×
π
π =2 . 5
(14) V
c
50
5
+→ c5 =2 . 5
(15) V
c
40 +→ c =2 . 5
(16) VF V
K F
44 +→ + KF =0 . 1
(17) dB dB B +→ +
α
a = 2.5 if T< 20
otherwise 0
(18) BF B
K B
+→ + KB =1 0
(19) BZ Z
Z
B
+→
δ
δ Z
B = 0.00001 if T <2 0
otherwise 0
(20) F
F
→
δ
0 δ
F= 0.001
(21) Z
b
→0 b =0 . 2
where I* stands for I4a n d
I5-t w or u l e s .
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(page number not for citation purposes)behaviour and their quantities. One or more entities can
participate synchronously to an event that causes a state
change. The state typically consists of the values of the
variables of the model. As seen, T cell infection is an
event to which virus strains and T cell participate. This
event leads to an increased number of infected cells, and
less T cells and viruses, which have been combined
together. Participation to events has stochastic rates
associated. The quantities of entities affect the stochastic
dynamics as expected. Figure 5 shows the code for T cell.
The variable tc keeps trace of the amount of T cells, then
two of the possible interactions for T cells are reported,
each consisting of a name, an integrity constraint, a rate
and an effect: [o2] generation of a new T cell, and [o5]
infection. The [o5] interaction is shared with Virus X4
and Ic e l l(see Table 2). As a consequence of the
occurrence of such interaction, the former decreases its
amount v4’ = v4 -1, which is required to be non-negative,
while the amount of the latter is instead increased. It is
worth noting how rates are defined so as to respect
stochastic semantics. Rates of synchronously executed
actions are multiplied to determine the overall rate of the
corresponding transition, i.e. the parameter of the
negative exponential distribution associated. In the case
of [o5], the overall rate is correctly determined by
multiplying the amount of Tc e l land Virus X4 together
with the rate Bk4. A PRISM model can be used for
simulation purposes, and for exact or approximated
model checking as illustrated.
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